213 related articles for article (PubMed ID: 25556263)
21. Müllerian adenosarcoma of the uterus: report of a case with imprint cytology.
Takeshima N; Tabata T; Nishida H; Arai Y; Tsuzuku M; Hirai Y; Yamauchi K; Hasumi K
Acta Cytol; 2001; 45(4):613-6. PubMed ID: 11480728
[TBL] [Abstract][Full Text] [Related]
22. Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management.
Tate K; Watanabe R; Yoshida H; Shimizu H; Uehara T; Ishikawa M; Ikeda SI; Hiraoka N; Kato T
Asia Pac J Clin Oncol; 2018 Aug; 14(4):318-325. PubMed ID: 29441675
[TBL] [Abstract][Full Text] [Related]
23. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
24. Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior.
Chen JW; Huang YJ; Wang LL; Liu JJ; Shi MM; Li N
BMC Womens Health; 2024 May; 24(1):308. PubMed ID: 38783282
[TBL] [Abstract][Full Text] [Related]
25. Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review.
Mandato VD; Torricelli F; Mastrofilippo V; Valli R; Aguzzoli L; La Sala GB
BMC Cancer; 2018 Feb; 18(1):134. PubMed ID: 29402239
[TBL] [Abstract][Full Text] [Related]
26. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
27. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases.
Omi M; Tonooka A; Chiba T; Tanaka Y; Fusegi A; Aoki Y; Nomura H; Kanao H; Takazawa Y
Diagn Pathol; 2020 Sep; 15(1):119. PubMed ID: 32972432
[TBL] [Abstract][Full Text] [Related]
29. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions.
Clement PB; Oliva E; Young RH
Int J Gynecol Pathol; 1996 Jul; 15(3):222-9. PubMed ID: 8811383
[TBL] [Abstract][Full Text] [Related]
30. Müllerian adenosarcoma arising in a subserosal adenomyoma.
Elshafie M; Rahimi S; Ganesan R; Hirschowitz L
Int J Surg Pathol; 2013 Apr; 21(2):186-9. PubMed ID: 22820101
[TBL] [Abstract][Full Text] [Related]
31. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.
Carroll A; Ramirez PT; Westin SN; Soliman PT; Munsell MF; Nick AM; Schmeler KM; Klopp AH; Fleming ND
Gynecol Oncol; 2014 Dec; 135(3):455-61. PubMed ID: 25449308
[TBL] [Abstract][Full Text] [Related]
32. Uterine Adenosarcoma Originating in Adenomyosis: Report of an Extremely Rare Phenomenon and Review of Published Literature.
Talia KL; Naaman Y; McCluggage WG
Int J Gynecol Pathol; 2021 Jul; 40(4):342-348. PubMed ID: 32947330
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological analysis of mullerian adenosarcoma of the uterus.
Han XY; Xiang Y; Guo LN; Shen K; Wan XR; Huang HF; Pan LY
Chin Med J (Engl); 2010 Mar; 123(6):756-9. PubMed ID: 20368100
[No Abstract] [Full Text] [Related]
34. Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ; Conley AP
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1093-1100. PubMed ID: 30169984
[TBL] [Abstract][Full Text] [Related]
35. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
36. A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman.
Farhat F; Fakhruddine N
Eur J Gynaecol Oncol; 2008; 29(1):95-7. PubMed ID: 18386476
[TBL] [Abstract][Full Text] [Related]
37. Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer.
Carvalho FM; Carvalho JP; Motta EV; Souen J
Rev Hosp Clin Fac Med Sao Paulo; 2000; 55(1):17-20. PubMed ID: 10881074
[TBL] [Abstract][Full Text] [Related]
38. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Bernard B; Clarke BA; Malowany JI; McAlpine J; Lee CH; Atenafu EG; Ferguson S; Mackay H
Gynecol Oncol; 2013 Dec; 131(3):634-9. PubMed ID: 24135678
[TBL] [Abstract][Full Text] [Related]
39. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
40. Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: A case report of aggressive disease in a young patient.
Morales F DA; Medina R ML; Trujillo LM; Beltrán MI; Dulcey IC
Int J Surg Case Rep; 2016; 27():155-161. PubMed ID: 27621097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
